US pharmaceutical firm, the Bristol-Myers Squibb (BMS) Company, aims to achieve sales of US$1 billion in China in 2010 in anticipation of the growing Chinese market and has adjusted its strategies accordingly.

Sales last year reached over 1 billion yuan (US$124 million).

"Asia is the most promising emerging market for BMS worldwide and China is the most promising in the region," said Cui Yiling, chairwoman of Sino-American Shanghai Squibb Pharmaceuticals Ltd, the flagship company of the global drug maker.